乌司奴单抗治疗克罗恩病的真实世界有效性与安全性:SUCCESS 联盟研究结果
该回顾性、多中心、跨国联盟研究纳入1113例接受乌司奴单抗治疗的克罗恩病患者(51.8%女性,90%曾暴露于抗肿瘤坏死因子),中位随访386天。12个月时临床、无激素、内镜和影像学缓解累积率分别为40%、32%、39%和30%,生物制剂初治患者临床和内镜缓解率分别达63%和55%。既往抗肿瘤坏死因子(HR 0.72,95%CI 0.49-0.99)和维得利珠单抗暴露(HR 0.65,95%CI 0.48-0.88)与较低的内镜缓解可能性独立相关。
要点
- 12个月临床缓解累积率为40%,无激素缓解32%,内镜缓解39%,影像学缓解30%。
- 生物制剂初治患者临床和内镜缓解率分别为63%和55%。
- 因失去缓解而剂量优化的102例中77例(75%)优化,其中44/77(57%)获临床应答。
核心结论
- 乌司奴单抗是克罗恩病安全有效的治疗选择,高度难治队列中40%的患者在12个月时达到临床缓解。
- 乌司奴单抗的最大治疗效应见于生物制剂初治患者,剂量升级可能重新获得临床应答。
研究设计与样本
- 回顾性、多中心、跨国联盟研究,纳入1113例接受乌司奴单抗治疗的克罗恩病患者。
- 采用时间-事件分析评估临床、无激素、内镜和影像学缓解的累积率,采用多因素 Cox 比例风险分析评估临床预测因素。
主要发现
- 12个月时临床、无激素、内镜和影像学缓解累积率分别为40%、32%、39%和30%。
- 生物制剂初治患者临床和内镜缓解率分别为63%和55%。
- 既往抗肿瘤坏死因子暴露(HR 0.72,95%CI 0.49-0.99)和维得利珠单抗暴露(HR 0.65,95%CI 0.48-0.88)与较低的内镜缓解可能性独立相关。
- 失去缓解的患者中,102例中77例(75%)接受剂量优化,77例中44例(57%)达到临床应答。
- 因原发无应答或不完全应答而剂量优化的681例中152例(22.3%),其中40.1%(152例中61例)有应答。
临床怎么用
- 乌司奴单抗可用于克罗恩病治疗,尤其生物制剂初治患者可能获得更高缓解率。
- 对失去应答的患者,剂量优化可能重新获得临床应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD). METHODS: This study used a retrospective, multicenter, multinational consortium of UST-treated CD patients. Data included patient demographics, disease phenotype, disease activity, treatment history, and concomitant medications. Cumulative rates of clinical, steroid-free, endoscopic, and radiographic remissions were assessed using time-to-event analysis, and clinical predictors were assessed by using multivariate Cox proportional hazard analyses. Serious infections and adverse events were defined as those requiring hospitalization or treatment discontinuation. RESULTS: A total of 1,113 patients (51.8% female, 90% prior antitumor necrosis factor exposure) were included, with a median follow-up of 386 days. Cumulative rates of clinical, steroid-free, endoscopic, and radiographic remissions at 12 months were 40%, 32%, 39%, and 30%, respectively. Biologic-naive patients achieved significantly higher rates of clinical and endoscopic remissions at 63% and 55%, respectively. On multivariable analyses, prior antitumor necrosis factor (hazard ratio, 0.72; 95% confidence interval, 0.49-0.99) and vedolizumab exposure (hazard ratio, 0.65; 95% confidence interval, 0.48-0.88) were independently associated with lower likelihoods of achieving endoscopic remission. In patients who experienced loss of remission, 77 of 102 (75%) underwent dose optimization, and 44 of 77 (57%) achieved clinical response. An additional 152 of 681 patients (22.3%) were dose-optimized because of primary nonresponse incomplete response to UST, of whom 40.1% (61 of 152) responded. Serious infections occurred in 3.4% of patients while other noninfectious adverse events (lymphoma [n = 1], arthralgia [n = 6], rash [n = 6], headache [n = 3], hepatitis [n = 3], hair loss [n = 3], neuropathy [n = 1], and vasculitis [n = 1]) occurred in 2.4% of patients. DISCUSSION: UST represents a safe and effective treatment option for CD, with 40% of patients from a highly refractory cohort achieving clinical remission by 12 months. The greatest treatment effect of UST was seen in biologic-naive patients, and dose escalation may recapture clinical response.
引用
- Johnson AM, Barsky M, Ahmed W, et al. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. Am J Gastroenterol. 2022. PMID: 36191274. doi:10.14309/ajg.0000000000002047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。